|
業務類別
|
Biotechnology |
|
業務概覽
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. |
| 公司地址
| 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 224-1000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.organovo.com |
| 員工數量
| 13 |
| Mr. Norman Staskey |
President, Principal Accounting Officer and Chief Financial Officer |
美元 20.93K |
03/11/2025 |
| Mr. Keith Murphy |
Executive Chairman of the Board and Principal Executive Officer |
美元 726.67K |
03/11/2025 |
| Mr. Tony Lialin |
Chief Commercial Officer |
-- |
14/08/2025 |
|
|
| Mr. Adam K. Stern |
Independent Director |
03/11/2025 |
| Mr. Keith Murphy |
Executive Chairman of the Board and Principal Executive Officer |
03/11/2025 |
| Mr. Douglas Jay Cohen |
Lead Independent Director |
03/11/2025 |
| Mr. David Gobel |
Independent Director |
03/11/2025 |
| Ms. Alison Tjosvold Milhous |
Independent Director |
03/11/2025 |
|
|
|
|
